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                                       ABSTRACT   
 
Treatment of OP poisoning includes continuous monitoring and timely intervention, 
ideally in an intensive care unit and is labour intensive.  In our setting where cost is 
a major factor and a large number of patients who are unable to afford care in an 
intensive care unit are treated even while they require mechanical ventilation in the 
general wards, a treatment regimen which is simple, easy to follow and includes 
fixed guidelines may be more easier, efficient and improve care in situations where 
ICU care is not possible immediately. 
 
This study attempted to formulate, based on the current practice and evaluate an 
algorithmic protocol of atropine in the management of moderate to severe acute 
organophosphate poisoning. The current study shows that use of a guideline may 
result in faster atropinisation and rapid stabilization of acutely sick patients who are 
treated initially in the emergency room. 
 
Conclusion: Administration of atropine using a fixed algorithm is easy and effective 
in providing the atropine requirement in the management of early phase of acute 
organophosphorus poisoning.  Smaller doses of atropine are sufficient in treating 
cases of OP poisoning, than those recommended in literature. This results in less 
atropine toxicity, without increasing complications. An algorithmic approach to 
atropine dosing appears promising.  
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INTRODUCTION 
 
Organophosphorus poisoning is one of the most common means of 
attempting suicide in India1.  This problem seems to be peculiar to India and 
other south asian countries as most of the compounds are available freely in 
the market as pesticides for agricultural use. In developing countries more 
than 90% of acute poisoning is due to suicidal attempt1. Most cases occur 
following occupational or deliberate exposure to organophosphorus pesticides. 
Although data are sparse, organophosphates appear to be the most important 
cause of death from deliberate self poisoning worldwide.2  
Organophosphate compounds inhibit both cholinesterase and pseudo-
cholinesterase activities. The inhibition of acetylcholinesterase causes 
accumulation of acetylcholine at synapses, and the resulting overstimulation of 
neurotransmission at the neuromuscular junction, disturbs transmission at 
parasympathetic nerve endings, sympathetic ganglia, neuromuscular 
endplates and certain CNS regions25.    
Early diagnosis and appropriate treatment is often life saving.  The 
early clinical course of OP poisoning may be quite severe and may need 
intensive care management.  Atropine is the mainstay of treatment of effects 
mediated by muscarine sensitive receptors. 
    Therapy requires the urgent use of atropine to reverse cholinergic 
excess, thereby improving respiratory function, heart rate, and blood 
pressure. 
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There is great variation in recommendations in textbooks for adequate 
dose of atropine18 and atropinisation of an average patient some times can 
take hours and even days to stabilize vital parameters.  
The dose of atropine is usually individualized to the patient’s heart 
rate, pupil size, respiratory secretions and levels of CNS arousal. The 
guidelines being variable it is difficult for an inexperienced junior doctor to 
follow18. Mortality following OP poisoning remains high despite adequate 
respiratory support, intensive care, and specific therapy with atropine 
especially in the early hours. Significant numbers of the subjects needing 
mechanical ventilation and reaching intensive care units die within the first 72 
h of poisoning. This may be because of failure to stabilize patients early 
during the course of illness.  On the other hand atropine overdose in itself 
may be responsible for adverse outcome especially in the elderly population.  
There is a trend towards using minimum doses of atropine and 
avoiding Oximes altogether as their efficacy is still controversial* and their 
use late in the illness may not be useful.  The optimum atropine dosage is not 
yet defined and under or overdosing with atropine is a common occurrence 
for sick patient presenting to emergency room.   
The present study was chosen to study the existing pattern of atropine 
administration in the treatment of acute organophosphate poisoning. It was 
felt that the knowledge gained by the study would allow the development of a 
simple protocol for atropine administration prospectively. 
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  The new simplified protocol should be easy to administer, should be 
effective in blocking the clinical effects of muscuranic stimulation without 
causing atropine toxicity. And should be able to speed up the initial time 
needed to stabilize a patient by achieving rapid atropinisation, and provide a 
regular dose in the form of infusion which is easy to administer and more 
physiological. 
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                                      AIMS 
 
The aim of the study is to evaluate the atropine dosing pattern 
currently in practice at the Department of general medicine, Christian Medical 
College and Hospital, Vellore; and thereafter to develop and evaluate a 
simple algorithm for atropine administration in the treatment of acute 
organophosphate poisoning. 
 
 
OBJECTIVES 
i) To study the dose requirement of atropine, for initial adequate 
atropinisation and subsequent requirement in the treatment of acute 
organophosphorus poisoning (Part I). 
ii)  To develop a simple algorithmic dose regimen of atropine using the 
results of the Part I study in treatment of acute organophosphate 
poisoning (Part II). 
iii)  To study the feasibility, safety, effectiveness and complications of the 
algorithmic dose regimen developed as above (Part II).  
 
 
                                          
 6
REVIEW OF LITERATURE 
 
Acute organophosphorus (OP) poisoning is a common problem in the 
developing countries 1,2. It probably kills about 300,000 people every year 3,4. 
Most deaths occur in the rural areas of the developing world 2. In countries like 
India deliberate self poisoning is the most common cause of death second to 
road traffic accidents 5.  Their widespread use as insecticides and easy 
availability has resulted in serious increase in poisoning.  The extent of acute 
pesticide poisoning in agricultural workers, particularly in less developed 
countries, has often been based on inadequate information. Epidemiological 
studies, relying mainly on hospital and poison centre data, have been biased 
towards the more severe poisonings, whereas field studies indicate that 
occupational pesticide poisoning is associated with less severe and minor 
effects. Many reports do not adequately distinguish between intentional, 
accidental and occupational pesticide poisoning statistics or are dominated by 
cases of intentional poisoning which, by their nature, result in severe or fatal 
results.  
 
Epidemiology: 
World health organization estimates suggest that more than 3 million 
cases of acute serious pesticide poisoning and 220,000 deaths occur 
worldwide annually, the majority being caused by organophosphates used for 
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agricultural purposes 1.   In the hospital based poisoning surveys from India 
59% of all admissions are due to pesticide poisoning6. 
In the Christian Medical College and Hospital, Vellore OP poisoning 
accounts for 12% of all medical intensive care unit admissions and 75% of all 
poisoning 7. In a recent study by Srinivas Rao et al from India  there were 
8040 admissions  in 6 years with an overall case fatality ratio of 22.6%, two 
thirds of  these were less than 30 years old, with 96% rates  of intentional 
poisoining8 . 
 
History: 
The first OP compound synthesized by Clermont in 1854 was tetraethyl 
pyrophosphate (TEPP).  It came into use during World War II as an 
agricultural pesticide substitute for nicotine and for use as a nerve gas in 
chemical warfare. It is also the most toxic of the OP insecticides. Modern 
investigations of OP compounds date from the 1932 publication of Lange and 
Krueger on synthesis of dimethyl and diethyl phosphoflouridates. Schrader 
described the structural requirements for insecticide activity of these 
compounds in 1952.  
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Pathophysiology of organophosphorus poisoning: 
The primary mechanism of action of OP pesticides is inhibition of 
acetylcholinesterase (AChE), which is an enzyme found in the nervous 
system. Its normal action is to break down acetylcholine (ACh). 
 
Figure 1: Action of acetylcholinesterase 
OPs inactivate AChE by phosphorylating the serine hydroxyl group located at 
the active site of AChE. The phosphorylation occurs by loss of an OP leaving 
group and establishment of a covalent bond with AChE. Once AChE has been 
inactivated, ACh accumulates throughout the autonomic ervous system, the 
somatic nervous system, and the brain, resulting in overstimulation of the 
muscarinic and nicotinic receptors.   
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Figure 2: Inactivation of AChE and accumulation of ACh in the synapse.  
(Figures reproduced from; Pharmacology, 4th edition. Rang HP, Dale MM and 
Ritter JM. Edinburgh, UK: Harcourt Publishers Ltd, 2001:110–138.) 
The preganglionic and postganglionic neurons in the parasympathetic nervous 
system release ACh. Postganglionic ACh acts on muscarinic receptors on the 
heart, eyes, glands, GI tract, and respiratory system.  Somatic motor axons 
emerge from the spinal cord and directly innervate muscle cells at the 
neuromuscular junction, releasing ACh on nicotinic receptors.  The brain and 
spinal cord both contain muscarinic and nicotinic receptors. Cholinergic 
pathways in the brain are associated with various behaviors and functions, 
including hunger, thirst, thermoregulation, respiration, aggression, and 
cognition.  
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Once an OP binds to AChE, the enzyme can undergo 3 processes, including 
(1)  Endogenous hydrolysis of the phosphorylated enzyme by esterases or 
paraoxonases,  
(2)  Reactivation by a strong nucleophile such as pralidoxime (2-PAM), and  
(3)  Biological changes that render the phosphorylated enzyme inactive 
(aged). 
Serine
Phosphorylated
serine
Phosphorylat
ed serine
Alkyl group removed
P2Am catalyses step 2
By transferring OH from itself
Rapid 
Slow
Rapid with
Dimethyl OPs
* 
Figure 3: Interactions between OP compound and AChE enzyme. 
  OPs can be absorbed cutaneously, or they can be ingested or inhaled. 
Onset and duration of action depend on the nature and type of compound, the 
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degree and route of exposure, the mode of action of the compound, lipid 
solubility, and rate of metabolic degradation. 
Clinical manifestations: 
 The signs and symptoms of acute organophosphate poisoning are 
due to the effects caused by excess acetylcholine (cholinergic syndrome); they 
can manifest at different times. Signs and symptoms can be divided into three 
groups: 
 -   Muscarinic effect: parasympathetic. 
-   Nicotinic effect: sympathetic and motor. 
-   Central nervous system effect: M1 muscuranic receptor stimulation.  
 
 The clinical syndrome of organophosphorus poisoning can be classified 
into 
1. Acute manifestations: The cholinergic phase (occurs within 0-24 hrs.). 
2. Intermediate syndrome: Due to persistent nicotinic effects of 
acetylcholine excess (Develops 24 to 96 hours after resolution of acute 
cholinergic symptoms and may persist for 4 to 18 days)   
3. Chronic manifestations: Delayed neurotoxicity due to axonal 
degeneration. 
           (Occurs 2-3 weeks after exposure to large doses and recovery may 
take upto 12 months.) 
 According to the degree of the severity of poisoning, the   following 
signs and symptoms can occur during the acute phase 11,12:- 
 12
  *Mild:   anorexia, headache, dizziness, weakness, anxiety, 
substernal discomfort, fasciculations of the tongue and 
eyelids, miosis, and impairment of visual acuity. 
*Moderate:  nausea, salivation, bronchorrhoea, lacrimation, abdominal 
cramps, diarrhoea, vomiting, sweating, hypertension or 
hypotension, and muscular fasciculations. 
*Severe:  miosis or mydriasis, non-reactive pupils, dyspnoea, 
respiratory depression, pulmonary oedema, cyanosis, loss of 
sphincter control, convulsions, coma, bradycardia or 
tachycardia, cardiac ischaemia, cardiac  dysrhythmias,  
hypokalaemia, and hyperglycaemia.  Acute pancreatitis has 
also occurred.  Muscular paralysis may involve the 
respiratory muscles. 
 
Muscarinic effects by organ systems include the following: 
Cardiovascular  - Bradycardia, hypotension 
Respiratory   - Rhinorrhea, bronchospasm, bronchorrhea, cough 
Gastrointestinal - Increased salivation, nausea and vomiting, abdominal  
      pain, diarrhea, and fecal incontinence 
Genitourinary  - Urinary incontinence 
Ocular   - Blurred vision, miosis 
Glands   - Increased lacrimation, increased sweating 
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Nicotinic signs and symptoms include muscle fasciculations, cramping, 
weakness, and diaphragmatic failure. Autonomic nicotinic effects include 
hypertension, tachycardia, pupillary dilation, and pallor. 
CNS effects include anxiety, restlessness, confusion, ataxia, seizures, 
insomnia, dysarthria, tremors, and coma. 
Neurological manifestations: 
Type I - Acute paralysis secondary to persistent depolarization at the 
neuromuscular junction. 
Type II  (intermediate syndrome) - Intermediate syndrome was described 
in 1974 by Wadia et al 13, with an incidence from 8-49%. It 
develops 24-96 hours after resolution of acute cholinergic 
poisoning symptoms and manifests commonly as paralysis and 
respiratory distress. This syndrome involves proximal muscle 
groups, with relative sparing of distal muscle groups. Various 
degrees of cranial nerve palsies also are observed. 
Neuromuscular transmission defect and toxin-induced muscular 
instability play a role in intermediate syndrome. Intermediate 
syndrome persists for 4-18 days, can require intubation, and can 
be complicated by infections or cardiac arrhythmias. 
Type III  - Organophosphate-induced delayed polyneuropathy (OPIDP) 
occurs 2-3 weeks after exposure to large doses of certain OPs. 
Distal muscle weakness with relative sparing of the neck 
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muscles, cranial nerves, and proximal muscle groups 
characterize OPIDP. Recovery can take up to 12 months. 
 Death in severe poisoning is likely due to effects on heart 
(bradycardia, arrythmias and hypotension), respiration (central or peripheral 
respiratory failure) and on the brain (depression of vital centres)9. 
The mechanism of cardiac toxicity is unclear and the following have all been 
postulated: 
1.  A direct toxic effect on the myocardium 
2.  Overactivity of cholinergic or nicotinic receptors causing haemodynamic 
alteration 
3.  Hypoxia 
4.  Acidosis 
5.  Electrolyte abnormalities 
6.  High dose atropine therapy. (used as treatment for organophosphate 
poisoning). 
 
Management: 
The following are the major aspects in the management of patients with 
acute organophosphorus poisoning. Despite the large number of pesticide 
poisoning cases occurring worldwide every year, the current evidence base in 
the management of acute organophosphorus poisoning is small 28.   
1. Asses breathing and circulation. 
2. Ensure adequate airway – suction of copious secretions and vomitus. 
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3. Ensure adequate oxygenation and ventilation. 
4. Anticholinergic drugs – atropine. 
5. Hemodynamic resuscitation.  
6. Removal of contaminated clothing (in cases of accidental exposure or 
spilling over body). 
7. Skin and mucus membranes decontamination. 
8. Control of convulsions. 
9. Monitoring of heart rate, blood pressure, oxygenation and level of 
consciousness. 
10. Gastric lavage. 
11. Oximes. 
12. Active cooling and sedation. 
 
Gastric decontamination  
1. Ipecacuanha has been used to induce emesis in poisoned patients. It 
takes 20-30min to work and vomiting may last for more 30min23. If loss 
of consciousness occurs during this time, intubation may be needed in 
an unconscious vomiting patient. Since patients with pesticide 
poisoning may suddenly deteriorate, ipecacuanha is contraindicated. 
Forced emesis in hospital using other techniques is ineffective23.    
 
2.  Gastric lavage is a routine practice in most cases of organophosphorus 
poisoning by oral route. The efficacy of gastric lavage falls rapidly with 
time since ingestion24. By the time most patients arrive in hospital, the 
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majority of pesticide will have passed into the small bowel, out of the 
reach of gastric lavage. Some diluted solvent may be left in the 
stomach – this will smell of ‘pesticide’ if sucked out with a NG tube. The 
volume of fluid in the stomach will appear large in cholinergic poisoning 
due to the secretion of fluid into the bowel25. However most of the 
hospital practices gastric lavage even up to 4-6 hours after thy intake of 
poison. 
3.  Activated charcoal is routinely advocated to “adsorb” ingested poison. 
 
There is currently no evidence that either single or multiple dose 
regimens of activated charcoal result in clinical benefit26,27.The practice of 
giving charcoal rests upon usual practice and is now being evaluated in an 
RCT (ISRCTN02920054).  
 
Giving fluids: 
There have been no studies on the effects of giving IV fluids in ill 
patients with OP poisoning. However, due to the cholinergic effects, these 
patients lose a great deal of fluid into their gastrointestinal tract and lungs, and 
onto their skin as sweat, resulting in intravascular fluid depletion. Some also 
develop severe diarrhea that results in fluid and potassium loss14.  
There is no evidence that giving fast IV fluid to patients with bronchorrhoea is 
dangerous as long as atropine is being given simultaneously to dry the lung 
secretions.  
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Oximes: 
Oximes reactivate the acetylcholinesterase by removing the phosphoryl 
group (reaction 2, figure1). Pralidoxime is the enzyme which is used most 
commonly worldwide. It occurs in two common forms: Pralidoxime chloride (2-
PAM, molecular weight 173) and Mesylate( molecular weight 232). 
 
In the following situations however reactivation of inhibited 
acetylcholinesterase will be absent or limited. 
1.  Poor affinity of the OP-AchE complex. 
2.  Insufficient dose or duration of treatment. 
3.  Persistence of the OP within the patient and hence rapid reinhibition of 
newly reactivated enzyme.  
4.  Ageing of the inhibited acetylcholinesterase.(reaction 3, figure 1). 
The clinical benefit of oximes for OP pesticide poisoning is not clear, 
being limited by the type of OP, poison load, time to start of therapy, and dose 
of oxime 29,30. Current World Health Organisation guidelines recommend 
giving a 30 mg/kg loading dose of pralidoxime over 10–20 min, followed by a 
continuous infusion of 8–10 mg/kg per hour until clinical recovery or 7 days, 
whichever is later 30,31.  However assessment of the primary outcomes in a 
recent meta-analysis indicated either a null effect or a tendency of harm with 
oxime therapy32.  
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At the Christian Medical College Vellore the practice of using oximes 
was stopped from 1999 following the results of studies reported in literature 
about a tendency of harm with oximes. The data during the “no oxime era” 
(1999-2005) for patients admitted in the adult medical intensive care unit is 
shown38. 
Year Total patients OP poisoning 
( % of total admission) 
Mortality of OP (%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
758 
787 
790 
759 
735 
697 
702 
111 (14.6) 
118 (15.0) 
112 (14.2) 
  99 (13.0) 
102 (13.9) 
101 (14.5) 
 82 (11.7) 
15 (13.5) 
17 (14.4) 
19 (17.0) 
14 (14.1) 
15 (14.7) 
14 (13.9) 
12 (14.6) 
 
Table 1: Mortality in OP poisoning of patients treated in ICU. 
The above data can be taken only as a benchmark for the mortality in 
patients without the use of oximes. It can not be compared with the earlier 
mortality during the oxime usage era, because the decline in mortality is 
probably multifactorial, including the improved standard of care in the medical 
intensive care unit over this period of time.  
The lack of current prospective randomized controlled trials, with 
appropriate patient stratification, mandates ongoing assessment of the role of 
oximes in organophosphate poisoning. 
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Active cooling and sedation: 
Hyperthermia is a serious complication in hot and humid wards. A 
febrile patient should receive the minimum amount of atropine needed to 
control muscarinic signs, sedation if there is excessive agitation and muscle 
activity, and active cooling. 
Reduce agitation with diazepam. Restraining a non-sedated agitated patient to 
the bed is associated with complications, including death. Such patients 
struggle against their bonds and generate excess body heat, which may result 
in hyperthermic cardiac arrest14. 
Diazepam is preferred over haloperidol because large doses of 
haloperidol may be required in patients receiving atropine. Haloperidol is also 
non-sedating, associated with disturbances of central thermoregulation and 
prolongation of the QT interval, and pro- convulsant. Diazepam may also have 
other advantages because animal studies suggest that it reduces damage to 
the central nervous system33 and diminishes central respiratory failure34. 
 
Anticholinergic drugs: 
Atropine is a specific antidote for the treatment of poisoning with 
organophosphorus and carbamate insecticides and organophosphorus nerve 
agents. 
Atropine is the best-known member of a group of drugs known as 
muscarinic antagonists, which are competitive antagonists of acetylcholine at 
muscarinic receptors. It has no effect at the nicotinic receptors. This naturally 
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occurring tertiary amine was first isolated from the Atropa belladonna plant by 
Mein in 1831.  Atropine earlier enjoyed widespread use in the treatment of 
peptic ulcer, today it is mostly used in resuscitation, anaesthesia, and 
ophthalmology.  It may also be used to counteract adverse 
parasympathomimetic effects of pilocarpine, or neostigmine administered in 
myasthenia gravis. The first report of atropine being used as an antidote for 
acetylcholinesterase inhibitors was by Fraser in 1870, he used atropine to 
counteract the effect of physostigmine on the pupil. Sanderson in 1961 
described the effect of intraperitoneally administered atropine given alone, or 
combined with oximes, on the survival of rats poisoned by 
organophosphates11. 
Textbooks list many features of the cholinergic syndrome 11,12 . 
However, in practice mainly the following five are used in routine assessment: 
miosis, excessive sweating, poor air entry into the lungs due to bronchorrhoea 
and bronchospasm, bradycardia, hypotension and fasciculations. If none of 
these signs are present, then the patient does not yet have clinical cholinergic 
poisoning and does not require atropine. Fasciculations are due to the 
depolarizing blockade at the neuromuscular junction as stated earlier, atropine 
does not reverse fasciculations. However, it is possible that these signs will 
occur later, for example as a pro-poison (thion) OP is converted to the active 
oxon form, as a fat-soluble OP such as fenthion leaches out of fat stores into 
the blood, or if the patient has presented soon after the ingestion. Careful 
observation is required to look for the development of cholinergic signs.  
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Giving atropine before oxygen: 
Although it is preferable that oxygen is given early to all ill patients, 
delay should not occur in giving atropine if oxygen is unavailable.  
Some reports suggest that atropine should not be given to a cyanosed 
patient until oxygen has been given - to reduce the risk of atropine inducing 
ventricular tachycardias11. While apparently sensible, such advice risks 
preventing doctors working in small rural hospitals from giving life-saving 
atropine treatment, since many do not have oxygen. Furthermore, in treatment 
of more than 800 patients receiving atropine, many of whom received atropine 
before oxygen, no patient had a cardiac arrest within minutes of giving 
atropine14. The primary evidence for an increased risk of a ventricular 
dysrhythmia from giving atropine to a cyanosed patient consists of very few 
patients. Since atropine dries secretions and reduces bronchospasm, its 
administration should reduce cyanosis. There is no good evidence that giving 
atropine to a cyanosed patient causes harm 14.  
 
Use of atropine  
Basic pharmacology and animal work suggests that early antagonism of 
pesticide toxicity should be associated with better outcomes 15,16. Although 
there are few studies on the subject, there is some evidence that patients in 
the developing world often die soon after admission17. Full and early 
atropinisation is an essential and simple part of early management. Delayed 
atropinisation can result in death from central respiratory depression, 
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bronchospasm, bronchorrhoea, severe bradycardia and hypotension25. Animal 
work suggests that these early deaths may be primarily due to central 
cholinergic stimulation15. 
The initial half life of distribution of atropine is about 1 minute11,22. After 
intravenous dosing, atropine distributes rapidly with only 5% remaining in the 
blood compartment after five minutes.  Studies in anesthetized patients 
indicate that the peak effect is seen within three minutes of an IV injection23. 
There is therefore no need to wait for more than five minutes before checking 
for a response and giving another bolus dose if no response has occurred. 
After intravenous dosing, atropine elimination fits a two-compartment model 
with an intrinsic clearance of 5.9-6.8 ml/kg/min and a plasma half-life of 2.6-4.3 
hours in the elimination phase11. In an emergency situation, it may be 
necessary to give atropine before intravenous or intraosseous access can be 
established. The endotracheal route has therefore been used, when vascular 
access was not available with success. The best regimen for the 
administration of atropine has not been established 11. A study performed in 
Bangalore, India, found that a regimen of bolus loading doses followed by an 
infusion improved outcome compared to repeated bolus doses 19 however, 
this study used historical controls which risks inflating benefit compared to 
RCTs 20,21. Although the benefit of infusions is not yet proven, the use of bolus 
loading doses followed by an infusion may save time, require less observation, 
produce less fluctuation in plasma atropine concentrations, and make weaning 
easier 11.  
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It is preferred to give low doses of atropine to start with and then rapidly 
escalate the dose. An alternative approach is to start with much bigger doses, 
to ensure rapid atropinisation, and then wait for the atropine levels to fall. 
Because of the dangers of over-atropinisation, however, the former practice 
offer more control by starting with low doses. It is difficult to distinguish 
patients who needed very large doses of atropine from those who required just 
a few milligrams18.  
There are various recommendations about the use of atropine in the 
treatment of organophosphorus poisoning. Eddleston et al *obtained thirty 
three different recommendations for atropinisation from clinical toxicology 
textbooks and electronic sources, national formularies, and international 
textbooks of internal medicine. 
The following is the atropine recommendations in text books, 
handbooks, and online databases of clinical toxicology as published by 
Eddleston et al in there study on comparison of recommended regimens of 
atropine18. 
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Dose recommended in the literature for atropine in treatment of acute OP 
poisoning. 
Source Edition/ 
year 
recommendation Maximum 
dose 24 hrs 
Atropine 
dose per 
hour. 
Harrisons text 
book of  
Medicine 
16th/2005 0.5-2mg repeated every 5-
15 minutes 
192 mgs 8 mgs/hour 
Davidsons text 
book of  
Medicine 
19th/2002 2 mg repeated every 10 
minutes 
288 mgs 12 mgs/hour 
British national 
formulary 
46th/2003  2mgs repeated every 5-10 
minutes 
576 mgs 24 mgs/hour 
Oxford textbook 
of  
Medicine 
4th/2003 2 mgs repeated every 10-30 
minutes 
288 mgs 12 mgs/hour 
WHO treatment 
guide 
1999 1-2 mgs repeated every 5-
10 minutes 
576 mgs 24 mgs/hour 
Poisindex OP  
Poisoning 
2003 2-5 mgs every 10–30 
minutes 
720 mgs 30 mgs/hour 
Ford  1st/2001 1-2 mgs repeated every 5 
minutes doubling the dose. 
Large Doses 
(100s of  
mgs) 
 
Reigart 5th/1999 If GCS normal: 2-4 mg 
every 15 min. 
If GCS reduced: 4-8 mg 
every 5-15 minutes.  
Large doses. 96 mgs/hour 
Fernando 2nd/1998 2-10 mg, then 2 mg 
repeated every 10-15 
minutes  
298 mgs. 12 mgs/hour 
 
Table 2:  Atropine dose recommendations in literature. 
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He calculated the time needed to achieve initial atropinisation by using 
these regimens on his 22 patients enrolled in the study. The patients required 
a mean of 23.4 mg (standard deviation 22.0, range 1–75 mg) atropine to clear 
the lungs, raise the pulse above 80 bpm, and restore systolic blood pressure 
to more than 80 mmHg. Textbook recommendations varied markedly — 
atropinisation of an average patient, requiring the mean dose of 23.4 mg, 
would have taken 8 to 1380 mins; atropinisation of a very ill patient, requiring 
75 mg, would have taken 25 to 4440 mins.  Thus there is great variation in 
recommendations for adequate dose of atropine. Thus there is a need to 
review the evidence for atropine administration and to produce and 
disseminate a simple guideline that will be useful for doctors faced by this 
severe form of poisoning across the world. Given the paucity of existing 
evidence, clinical studies looking to determine the optimal dosing regimen of 
atropine that rapidly and safely achieves atropinisation in these patients are 
required. 
Criteria for atropinisation  
Patients die acutely from respiratory or circulatory failure, the former of 
which is exacerbated by bronchospasm and bronchorrhoea. All respond to 
atropine treatment. 
There are no comparative studies of markers for adequate 
atropinisation18. In particular, since current endpoints do not include a CNS 
endpoint, it is possible that atropinisation is not reversing the CNS cholinergic 
syndrome, which may have significant effect on preventing early death from 
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OP poisoning 15. In practice, air entry on chest auscultation, heart rate, and 
blood pressure are the main parameters used for adequate atropinisation.  
Furthermore, both dilated pupils and tachycardia can result from stimulation of 
nicotinic ACh receptors, and tachycardia result from low total peripheral 
resistance with a partially compensatory high cardiac output35. 
In summary the target end point to atropine therapy14: 
a) Clear chest on auscultation with no wheeze 
b)  Heart rate >80 beats/min 
c)  Pupils no longer pinpoint 
d)  Dry axillae 
e)  Systolic blood pressure >80 mmHg 
 
Atropine toxicity  
There has been a tendency among clinicians to advocate over-
atropinisation to reduce the risk of them being under-atropinised. However, 
atropine toxicity has its risks and complications. Hyperthermia is a particularly 
serious complication in the hot wards of the developing world. Initial CNS 
stimulation leads to severe agitation. Agitated patients in ambient 
temperatures greater than 35C, not sweating because of atropine, can 
become very hot. Hyperthermia resulting from the high ambient temperatures 
is exacerbated by intense muscle activity due to atropine-induced agitation 
and failure of sweating, and sometimes if the patient is an alcoholic, then the 
situation is worsened due to delirium tremens. Endpoints such as pulse rates 
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>120/min and totally dilated pupils suggest that the patients are being given 
too much atropine.  A further problem with fast heart rates is ischaemic heart 
disease in elderly patients. There are reports of patients with fairly mild 
poisoning who died in ICU from myocardial infarctions after being given 
atropine to keep their heart rate at 120–140 bpm18. Other complication of 
atropine usage includes paralytic ileus, urinary retention, and precipitation of 
glaucoma and hypersensitivity reactions11. 
 
Glycopyrronium bromide (glycopyrrolate) 
Glycopyrronium bromide has been used instead of atropine because it 
is thought to have fewer adverse effects on the central nervous system. There 
are no randomized controlled trials comparing glycopyrronium bromide 
(glycopyrrolate) versus placebo, but it is unlikely that such a trial would be 
considered ethical unless glycopyrronium bromide and placebo were 
administered in addition to atropine. One small randomized controlled trial 
found no significant difference in mortality or ventilation rates between 
glycopyrronium bromide and atropine, but it may have lacked power to detect 
clinically important differences37.  
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Conclusion: 
The above review shows that there is a lacuna in information on the 
requirement of atropine in the management of acute organophosphorus 
poisoning. Although there are reports of patient being managed with both low 
and high dose atropine there are no recommendations or human studies or 
any formulated protocol in the treatment of organophosphorus poisoning. 
This study is designed to be a prospective descriptive analysis of the 
current dosing practice of atropine being used in the department of medicine 
(Part I). 
The data will be used to develop a dosing protocol and this protocol will 
be prospectively evaluated in the treatment of acute organophosphorus 
poisoning (Part II). 
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MATERIALS AND METHODS 
 
 
The study was performed in two parts, Part I & II. 
 
PART I: 
A prospective descriptive analysis of the current dosing practices of 
atropine at Christian Medical College Hospital Vellore in the treatment of 
acute organophosphate poisoning and thereafter to develop a simple 
algorithm based treatment regimen for atropine administration in the 
treatment of acute organophosphate poisoning. 
 
PART II 
A prospective clinical evaluation of a simple algorithm based treatment 
regimen for atropine administration in the treatment of acute organophosphate 
poisoned adults admitted to Christian Medical College Hospital Vellore for the 
treatment of acute organophosphate poisoning. 
The study was approved by the research committee of the Christian 
Medical College Hospital Vellore and a research grant was sanctioned by the 
committee for the expenses incurred during the study.   
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STUDY FLOW DIAGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organophosphate poisoned individuals admitted between  
1st September 2004 and 31st May 2005 identified and screened 
for enrollment in part I study.  (n = 61) 
Patients excluded 
Mild poisoning (n = 24)  
Discharged at request, against medical 
advice within first 4 days. (n= 1)
Patients enrolled for part I study (descriptive analysis of the 
current dosing practices of atropine).  (n= 36) 
Data from Part I study analyzed and used in the formulation of 
an algorithmic protocol of atropine in the treatment of acute 
organophosphate poisoning. 
All individuals admitted with poisoning between  
1st February 2006 and 15th August 2006.  (n = 104) identified 
and screened for enrollment in study evaluating the above 
derived protocol. 
Patients excluded 
Non OP poisoning (n= 62) 
Mild OP poisoning as per Namba scale (n=15) 
Refused to participate (n=2) 
Patients enrolled for part II study. (Evaluation of a simple 
algorithm based treatment regimen for atropine administration in 
the treatment of acute OP poisoning).  (n= 25) 
All patients (n=25) followed up till discharge and Data analyzed. 
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STUDY DESIGN - PART I 
 
A prospective descriptive analysis of the current dosing practices of 
atropine at Christian Medical College Hospital Vellore in the treatment of acute 
organophosphate poisoning and thereafter to develop a simple algorithm 
based treatment regimen for atropine administration in the treatment of acute 
organophosphate poisoning. 
 
Population studied: 
Adult population (aged 12 years or older) with moderate to severe 
poisoning admitted to the emergency ward of Christian Medical College 
Hospital Vellore after definite history of organophosphate poisoning or with 
clinical evidence of organophosphate poisoning within 48 hours of poisoning. 
 
Inclusion criterion: 
1.  History of organophosphate poisoning (within 48 hours of poisoning.) 
or  
2.  Signs of organophosphate poisoning (at least one of the following four 
signs— brochorrhea, miosis, fasciculation, bradycardia) and 
3.  Low serum pseudocholinesterase level(less than 25% of normal) with 
4.  Moderate or severe poisoning(Namba scale). 
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Exclusion criterion: 
1.  Admission after 48 hours of poisoning. 
2.  Carbamate or other poisoning. 
3.  Patients with mild poisoning assessed by the Namba scale36  
(appendix 1). 
4.  Patients with known systemic illness like malignancy, chronic lung 
disease, renal or hepatic failure.  
5.  Pregnancy. 
 
MATERIALS AND METHODS PART I: 
All consecutive patients with organophosphorus poisoning or clinically 
suspected organophosphorus poisoning who fulfilled the inclusion criterion, 
admitted to the Christian Medical college hospital Vellore between 1st 
September 2004 and 31st May 2005 were enrolled into the study. Data was 
prospectively collected from the inpatient records during their treatment and 
patients were followed up till discharge from the hospital. Based on the data 
collected a dosing regimen was evolved for the treatment of acute 
organophosphorus poisoning. The treatment was carried out as per the 
current practices in the hospital. All the decisions regarding the treatment of 
the patient was made by the treating team. 
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Clinical assessment: 
Daily assessment and documentation of the hourly atropine 
requirement, atropine toxicity, in hospital events, complications, onset of 
intermediate syndrome, requirement for mechanical ventilation, tracheostomy 
and duration of mechanical ventilation were documented according to the 
clinical proforma (Appendix 2) by the investigator till the patient was 
discharged from the hospital for both parts of the study. 
 
Assessment of severity of poisoning 
The severity of poisoning was assessed by the Namba scale36 
(appendix 1). The poisoned patients were divided into three categories, mild, 
moderate and severe. Only patients with moderate or severe poisoning were 
included in the study.  
 
Diagnosis of intermediate syndrome: 
Intermediate syndrome was defined as proximal muscle weakness of 
Grade 3 or less, 72 hrs after poisoning with or without requirement of 
mechanical ventilation. 
 
Markers used to asses’ atropine toxicity 
Confusion, pyrexia, absent bowel sounds or urinary retention were 
used mainly in the diagnosis of atropine toxicity. Other possible reasons for 
the mentioned features were excluded. 
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Outcome measures 
1.  Duration of hospital stay was calculated from the time of admission to 
the discharge of  the patient from the hospital, measured in days. 
2.  Duration of ICU stay: from admission to discharge from medical ICU 
measured in days.   
The patients are transferred from the medical ICU on the basis of the 
following criterion 
a.  Off ventilatory support for 24 hours 
b.  Hemodynamically stable 
3. Need for ventilation  
 
The need for ventilation was based on the following guidelines 
a. Respiratory rate of more than 30/min. 
b. Shallow breathing 
c. Oxygen saturation of < 90% or PaO2 < 60 mmHg or            
  PCO2 > 50 mm Hg. 
4.  Duration of ventilation: Time till mechanical ventilation was 
discontinued. This included weaning time. 
5.  Intermediate syndrome: 
Presence or absence of intermediate syndrome was assessed in each 
case according to the criterion laid down earlier. 
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6.  Infections: 
Most common infections in these patients viz. Aspiration pneumonia, 
ventilator associated pneumonia, thrombophlebitis, blood stream 
infection, catheter related infections, skin and tracheostomy site 
infection and exposure keratitis was looked for in each patient. 
7.  Other hospital related morbidities like occurrence of acute renal failure, 
pancreatitis, hepatic dysfunction, arrythmias, cardiac arrest and 
atropine toxicity was also documented. 
8. Mortality 
Death occurring due to any cause was considered to be directly or 
indirectly due to the poisoning. 
 
Patients lost to follow up 
These were patients who were taken away by the relatives due to 
monetary constraints, futility of the situation etc. These patients were counted 
as “dead” for the analysis. 
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MATERIALS AND METHODS PART II 
 
A prospective clinical evaluation of a simple algorithm based treatment 
regimen for atropine administration in the treatment of acute organophosphate 
poisoned adults admitted to Christian Medical College Hospital Vellore for the 
treatment of acute organophosphate poisoning. 
 
EVOLUTION OF THE PROTOCOL TO BE USED IN PART II OF THE 
STUDY. 
The study protocol was based on the results of the data obtained in the 
part I study, also considering the literature recommendations and the 
feasibility in general practice. 
The dose distribution was not similar between patients and there were 
major variations in atropine requirement among the patients treated. The dose 
requirement did not follow a normal bell shaped distribution curve. In order to 
prevent the skewed data from affecting the dose to be followed in the protocol 
standard deviation was considered not useful in deriving the dosing protocol 
using our data. The mean values and the total requirement were 
predominantly considered. The cumulative mean atropine requirement on day 
1 was 60 mgs which decreased to 22.8 mgs on day 2, however the range 
varied from 0-256 mgs. Subsequent atropine requirements were minimal 
except for few patients.  The atropine dosage did not follow a definite pattern 
and hence any statistically derived mathematical formula to predict the dose 
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requirement was not possible using our data. Based on the obtained data, 
considering the wide variation in requirement among individual patients and 
the maximum dose being 60 mgs on day 1, the following simple protocol was 
derived.  
 
Intervention studied 
The following protocol was defined and studied. 
The patients were stabilized with the following regimen before atropine 
infusion protocol was initiated. This was done to ensure rapid stabilization. 
Initial atropinisation protocol:  
Inj Atropine sulphate 2 mg iv stat and double the dose and repeat 
every 5 minutes till Blood pressure > 90 systolic, Heart rate > 100 pm, no 
wheeze/crackles on auscultation 
Atropine infusion protocol (Study protocol): 
 DAY 1:  Atropine infusion at 5 mg/hour x 2hrs 
                                                  4 mg/hour x 2 hrs 
                                                  3 mg/hour x 2 hrs 
                                                  2 mg/hour x 18hrs    
DAY 2:  Atropine infusion at  2 mg/hour. 
DAY 3:  Atropine infusion at  1 mg/hour. 
DAY 4:  Atropine infusion at   0.5 mg/hour. 
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Prescribed deviation in the atropine dosing. 
In case of a decline in heart rate to less than 100 bpm on day 1 and 60 
bpm on day 2 onwards 1mg atropine intravenous boluses to be repeated 
every 3 minutes. 
In case of persistent tachycardia HR > 120bpm atropine infusion can 
be lowered by 1 mg/hour.In case of persistent tachycardia HR > 120bpm 
atropine infusion can be lowered by 1 mg/hour.  
All other supportive measures were given as required and the day to 
day decisions on management will be made by the concerned unit physician. 
Oximes like Pralidoxime (P2AM)  were not used in the treatment. 
 
Population studied: 
Adult population (aged 12 years or older) with moderate to severe 
poisoning admitted to the emergency ward of Christian Medical College 
Hospital Vellore after definite history of organophosphate poisoning or with 
clinical evidence of organophosphate poisoning within 48 hours of poisoning. 
The inclusion and exclusion criterion were the same as mentioned 
before for part I study. 
Method of recruitment of patients for the evaluation of study regimen. 
All consecutive patients with organophosphorus poisoning or clinically 
suspected organophosphorus poisoning who fulfilled the inclusion criterion, 
admitted to the Christian Medical college hospital Vellore between 1st 
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february 2006 and 15st August 2006 were enrolled into the study. Arrival of 
the patients was informed to researcher by the emergency unit staff on 
arrival. The initial management including stabilization and initial atropinisation 
was carried out by the emergency unit staff according to individual needs till 
the patient was enrolled into the study. All suitable patients were enrolled into 
the study as per the inclusion and exclusion criterion and further management 
was done according to the intervention protocol. 
 
Method of implementation of the study protocol: 
On arrival to the emergency room, the patients were screened and 
enrolled into the study. The stabilization was carried out in the emergency 
ward and patients were monitored using continous ECG monitor, pulse 
oximetry and blood pressure. Atropine boluses were used for the initial 
atropinisation. After achieving the target blood pressure and heart rate the 
patients were given planned atropine infusion as per the protocol. 
Initially the atropine infusion was administered by using microdrip 
intravenous sets in the emergency room. Once stable, the patients were 
shifted to the ward or ICU. The instructions regarding the study protocol was 
documented for administration by the nursing staff and they were instructed 
regarding the same. In the ICU, patients were monitored continuously. In the 
event of bradycardia, patient was given atropine bolus dose by the nursing 
staff, to achieve the target heart rate as planned. The reason for change in the 
dose of atropine planned was documented. The infusion rate was decreased 
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in the event of a tachycardia. Vital parameters were recorded continuously in 
the ICU and at least hourly in the ward on the first day. The decision for 
intubation and shifting to ICU if required was taken by the treating physician. 
The patients were examined daily and the hourly dose administered, the 
hospital events and complications were documented by the researcher. Data 
was also collected from the inpatient hospital records. Patients were also 
examined regularly by the treating physicians and all the decisions regarding 
the daily management was taken by them. The decisions regarding duration of 
ventilation, tracheostomy and antibiotic usage was also decided by them. 
The patients were assessed daily till discharge from the hospital.  
Clinical assessment: 
Daily assessment and documentation of the hourly atropine 
requirement, atropine toxicity, in hospital events, complications, onset of 
intermediate syndrome, and requirement for mechanical ventilation, 
tracheostomy and duration of mechanical ventilation were documented 
according to the clinical proforma (Appendix 2) by the investigator till the 
patient was discharged from the hospital for both parts of the study. 
Assessment of severity of poisoning: 
The severity of poisoning was assessed by the Namba scale36 
(appendix 1). The poisoned patients were divided into three categories, mild, 
moderate and severe. Only patients with moderate or severe poisoning were 
included in the study.  
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Assessment of the duration of the cholinergic crisis 
This was defined by the duration of atropine use in days. 
 
Diagnosis of intermediate syndrome: 
Intermediate syndrome was defined as proximal muscle weakness of 
Grade 3 or less, 72 hrs after poisoning with or without requirement of 
mechanical ventilation. 
 
Outcome measures  
As mentioned previously for the part I study. 
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RESULTS – PART I 
A total of 36 patients admitted to the Christian Medical college hospital 
Vellore between 1st September 2004 and 31st May 2005 with moderate to 
severe organophosphorus poisoning were enrolled in the study according to 
the inclusion criterion.  
SEX DISTRIBUTION: There were 24 (66.7%) were males and 12 females. 
(Figure4). 
 
  
 
 
 
 
 
 
Figure 4: Sex distribution of the population studied.  
AGE: The average age of the patients was 29.7 years (range 15 – 72 years) 
with 85% of our patients being less than 40 years old.  
Age groups Males n=24 Females n=12 Total n=36. 
12-20 yrs 6 2 8 
21-40 yrs 14 10 24 
>40 yrs 4 0 4 
 
Table 3: Age distribution of patients with OP poisoning. 
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PSYCHIATRIC EVALUATION: 
 In only 10 ( 27.8%) patients  evaluation by a psychiatrist revealed any 
factors  for which any specific treatment was needed , the rest of the suicide 
attempts were either accidental or due to an impulsive act secondary to an 
acute stress situation (Figure 5 ).  
 
 
 
 
 
 
 
Figure 5: Reason for poisoning. 
This emphasizes that suicidal attempts in most instances are due to an acute 
stress and the patient mostly leads a normal life after recovery.  
CLINICAL FEATURES: The clinical features at admission are given in table. 
Clinical findings Number, total n=36 Percentage % 
Miosis 20 55.6 
Pulmonary secretions 19 52.8 
Bradycardia 10 27.8 
Hypertension 5 13.9 
Crackles/wheeze 10 27.8 
Required intubation at 
admission 
15 41.7 
Table 4: Clinical features at admission. 
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ATROPINE DOSING:  
The atropine requirement of the patients during the first four days of 
there treatment is given below in Table5. 
Atropine dose Range(mgs)
 
Mean(mgs) Std. Deviation Median Mode 
hour 1 0-40 6.6 7.1 5 10 
hour 2 0-36 3.6 8.5 1 0 
hour 3 0-40 3.2 7.6 1 0 
hour 4 0-16 2.0 3.7 1 0 
hour 5 0-8 1.5 1.8 1 0 
hour 6 0-10 1.4 2.1 1 0 
hour 7 0-12 1.5 2.6 1 0 
hour 8 0-12 1.6 2.4 1 0 
hour 9 0-18 2.7 4.6 1 2 
hour 10 0-12 1.7 2.3 1 1 
hour 11 0-12 1.8 2.4 1.5 0 
hour 12 0-12 1.9 2.4 1.5 2 
hours 13TO24 0-144 30.6 36.7 21 0 
DAY2 0-256 22.8 43.9 11 0 
DAY3 0-222 11.0 37.1 0 0 
DAY4 0-86 3.3 14.3 0 0 
Table 5: Dose of atropine utilized in the treatment of acute 
organophosphate poisoning. 
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The mean total dose requirement of atropine for treatment on day 1 
was 60 mgs. Figure shows the mean hourly requirement of atropine during the 
first 12 hours of treatment in the hospital. 
 
 
 
 
 
 
 
 
Figure 6: Atropine requirement in the first 12 hours. 
The Following graph shows the mean atropine requirement over first four days 
of treatment after admission.  
 
 
 
 
 
 
 
 
Figure7: Atropine requirement during first four days. 
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ATROPINE TOXICITY: 
Only 3(8.3%) patients had atropine toxicity during the course of 
treatment in the hospital (Figure 8).  
 
 
 
 
 
 
 
 
Figure8: Atropine toxicity observed during treatment. 
PSEUDOCHOLINESTERASE LEVEL: 
The mean pseudocholinesterase level at admission was 902.1(range 127-
5850), Figure 9.  
 
 
 
 
 
 
 
Figure 9: Pseudocholinesterase levels in individual patients. 
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INTERMEDIATE SYNDROME: 
A total of 17(47.2%) patients developed intermediate syndrome, Figure 10.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Incidence of intermediate syndrome. 
 
ANTIBIOTIC USAGE: 
The prevalence of use of antibiotics in the management of patients was 
88.9% (n=32) and an infection most commonly respiratory or urinary was 
documented in 86% (n=31) of patients.  The antibiotic use increased with 
increase in the hospital stay. Fever, leucocytosis is a common feature which 
occurs early in OP poisoning and does not necessarily mean an infection.  
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VENTILATION: 
The mean duration of ventilation was 188.7 hours (range 0- 552, SD 
165.99) Figure 11. The mean duration of ventilation among patients who 
developed intermediate syndrome was 319.1 hours and 65.2 hours in patients 
who did not develop intermediate syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Duration of ventilation. 
Once managed through the acute phase the patients with moderate and 
severe poisoning who develop intermediate syndrome usually require long 
duration of ventilation. Prolonged ventilation is the major cause for 
complications and its associated morbidity and mortality in addition to the cost 
burden. 
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MORTALITY: 
The overall mortality due to organophosphate poisoning in the cases studied 
was 8.3 % (n=3), Figure 12.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Mortality in organophosphorus poisoning. 
The cause of death was due to cardiovascular collapse in the early 
cholinergic phase of poisoning in all patients.  
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RESULTS - PART II 
 
A total of 104 patients who were admitted with poisoning to the 
Christian Medical College Hospital Vellore between 1st February 2006 and 15th 
August 2006 were screened for eligibility. A total of 58 patients were admitted 
due to insecticide poisoning. 42 admissions were due to organophosphorus 
poisoning. 25 patients with moderate to severe poisoning were included in the 
study after informed consent was taken. 15 patients with organophosphorus 
poisoning had only mild poisoning and hence were excluded. 2 patients were 
not enrolled due to failure to obtain informed consent from the family.  
 
Baseline characteristics: 
AGE & SEX 
The mean age of patients was 26.8 years (range 15-66 yrs). There 
were 16(64%) males. 
 
Age groups Males n=16 Females n=9 Total n=25. 
12-20 yrs 1 5 6 
21-40 yrs 13 4 17 
>40 yrs 2 0 2 
 
Table 6: Age distribution of patient’s in Part II study. 
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OP COMPOUND: 
In only 12(48%) patients the exact compound ingested was known and 
only 4(16%) of patients were known to be poisoned by a dimethyl compound. 
On an average 80.52 ml was consumed by 19 people the amount consumed 
by the rest was not known. 
 
 
 
PRE HOSPITALISATION TREATMENT:  
14 (56%) patients presented to the hospital after gastric lavage at a 
local hospital. 
About 36% of patients had received atropine in some form before 
admission to the hospital. Only 1(4%) patient had received treatment with 
pralidoxime before admission and 1 patient was intubated at a local hospital 
and referred here for further treatment. 
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CLINICAL FEATURES: 
At admission to the emergency room the following were the baseline 
characteristics. 
Features at admission Frequency Percentage of total 
(n=25) 
Bradycardia 9 36 % 
Hypotension 2 8 % 
Miosis 18 72 % 
Paradoxical respiration 11 44 % 
Seizures 1 4 % 
Electrolyte abnormality 13 52 % 
Tachycardia 6 24 % 
Hypertension 2 8 % 
Mydriasis 0 0 % 
Respiratory arrest 3 12 % 
Acute renal failure 1 4 % 
Aspiration pneumonia 3 12 % 
Tachypnea 13 52 % 
leucocytosis 11 44 % 
Pre admission gastric lavage  14 56% 
Pre admission treatment with 
atropine 
9 36% 
Pre admission oxime treatment 1 4% 
Intubation before admission 1 4% 
 
Table 7: Baseline clinical characteristics at enrollment. 
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GCS AT ADMISSION: 
The following graph depicts the GCS (Glasgow Coma Scale) score for 
all the patients enrolled into the study at admission. 
GCS at admission
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Figure 14: GCS scores of patients at admission to hospital. 
PSEUDOCHOLINESTERASE LEVELS: The mean pseudocholinesterase 
level was 570.2 IU/L (range 190-3459 IU/L, SD 628.6). 
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Figure 15: Pseudocholinesterase levels at admission in study patients. 
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INTERMEDIATE SYNDROME: Intermediate syndrome developed in 10(40%) 
of patients. The mean onset time for the development of intermediate 
syndrome was 4.1 days (range 1-7 days, SD 2.02). 
 
 
INITIAL ATROPINISATION: 
The mean atropine required for intial atropinisation of a patient was 
8.88 mg (range 0-34mg, SD 9.12). The bar diagram below shows the 
required doses for initial atropinisation in all 25 patients enrolled into the 
study. 
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Figure 16: Dose of atropine (mgs) required for initial atropinisation.
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PROTOCOL VIOLATIONS: The numbers of patients deviating from the 
protocol (either needing more or less than planned dose) were taken as 
protocol violations. The data is given in the table 8. 
Timing Planned  
dose of 
atropine 
(mg) 
Number stable 
on the 
planned dose. 
Number of 
protocol 
violation. 
Number 
requiring more 
than planned 
dose. 
0-2 hrs 10 21(84%) 4 1(4%) 
3-4 hrs 8 16(64%) 9 3(12%) 
5-6 hrs 6 13(52%) 12 5(20%) 
7-8 hrs 4 16(64%) 9 7(28%) 
9- 24hrs 32 13(52%) 12 6(24%) 
Day 1 60 5(20%) 19 9(36%) 
Day2 48 7(28%) 17 6(24%) 
Day 3 24 4(16%) 20 4(16%) 
Day4 12 2(8%) 18 3(12%) 
 
Table 8: Patient’s deviating from the protocol, during treatment with 
fixed planned regimen of atropine.  
The number of protocol violations increased with time and the initially 
planned dose was not unacceptable in a significant number of patients beyond 
6-8 hours. However the number of patients which needed more than the 
planned dose (clinically more important) were less, compared to the people 
who needed less than the planned dose.  
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The following were the reasons for protocol violations in the group of patients 
studied. 
 
 
Reasons for protocol violation 
Timing Number 
of 
protocol 
violation 
n=25 
Number 
requiring 
more than 
planned 
dose. 
Control 
of heart 
rate   
Reduce 
secretions
Low blood 
pressure 
Cardiac 
arrest 
0-2 hrs 4 1    1 
3-4 hrs 9 3 1 2   
5-6 hrs 12 5 3 1 1  
7-8 hrs 9 7 9    
9- 24hrs 12 6 5   1 
Day 1 19 9 9    
Day2 17 6 5  1  
Day 3 20 4 4    
Day4 18 3 3    
 
Table 9: Causes for increased atropine requirement and time of 
occurrence. 
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Table 10: Causes for decreased atropine requirement and time of 
occurrence. 
OUTCOMES: 
A total of 16 (64%) patients needed mechanical ventilation during the 
treatment. The mean duration of ventilation was 10.87 days (range 1-21 days, 
SD6.69).  
                            
                        Reasons for protocol 
violation 
Timing Number 
of 
protocol 
violation 
n=25 
Number 
requiring 
less than 
planned 
dose. 
Control 
of 
heart 
rate   
pyrexia confusion Urinary 
retention 
0-2 hrs 4 3 3    
3-4 hrs 9 6 4   2 
5-6 hrs 12 7 5 1 1  
7-8 hrs 9 2 2    
9- 24hrs 12 6 4  2 1 
Day 1 19 10 3 1 3 3 
Day2 17 11 11    
Day 3 20 16 16    
Day4 18 15 15    
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Figure 17: Duration of mechanical ventilation during treatment. 
 
 Tracheostomy was performed on 9(36%) of patients and the mean 
day of performing tracheostomy from admission was 6.78 days (range 5-10 
days, SD 1.48). 
The mean duration of hospital stay was 11.08 days (range 1-28 days, SD 
8.61). 
 
MORTALITY 
Total of 22 (88%) of patients survived and were discharged in a normal 
state. The all cause mortality related to poisoning was 12%.  
Mortality in OP poisoning.
Alive, n=22
(88%)
Dead ,n=3 
(12%)
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Figure 18: Mortality in the treatment of acute OP poisoning. 
 
COMPLICATIONS: 
The following complications were observed during the treatment in the 
hospital. 
In hospital 
complications 
Frequency Percentage of total 
Cardiac arrest 5 20 % 
Hypotension 4 16 % 
Aspiration pneumonia 9 36 % 
Nosocomial pneumonia 7 28 % 
Septicemia 2 8 % 
Acute renal failure 1 4 % 
Hepatic dysfunction 0 0 % 
Pancreatitis 0 0 % 
Atropine toxicity 2 8 % 
Mechanical ventilation 16 64% 
 
Table11: Complications during treatment in hospital. 
 
During the treatment period after initial atropinisation and stabilization, 
when the atropine infusion was given as per the fixed protocol and patient’s 
heart rate, blood pressure, wheeze, secretions were closely monitored.  
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ATROPINE TOXICITY: Atropine toxicity was noticed in only 2(8%) of the 
patients treated with the regimen. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Development of atropine toxicity on treatment. 
The low incidence of atropine toxicity is due to usage of low doses in 
our infusion protocol and also prompt reduction in the dose required if needed 
due to regular monitoring. 
 
 
 
0
5
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20
25
number of 
patients
1 2
      1- number developed toxicity n=2,
2- number without toxicity n=23.
observed atropine toxicity
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DISCUSSION 
Published literature is very sparse in the area of guidelines for adequate 
atropinisation in OP poisoning. Over several years the department of medicine 
at Christian medical college hospital, Vellore has found that keeping the heart 
rate at or around 100 beats per minute and ensuring absence of crackles on 
lung auscultation, are the two most important end points for adequate 
atropinisation. Pupillary size and assessment of central nervous stimulation 
have not been found useful (unpublished communication). Therefore heart 
rate and crackles were used as the main indicators of adequate atropinisation, 
in this study. 
The results of the observational study (Part 1), indicates that the 
cumulative mean dose of atropine used in the first 24 hours was 60 mgs. This 
dose is significantly less than the published recommendations.  A perusal of 
individual values shows a very wide range of doses, and the values do not 
show a Gaussian distribution. Therefore the median and mode values were 
considered, and these indicated very small doses. 
The atropine doses recommended in the published literature are not 
comprehensively stated. The doses mentioned seem to indicate the initial high 
doses needed for the first 8 to 12 hours. If the recommended doses are 
extrapolated over a 24 hour period then most recommendations would 
advocate doses of 192 mgs to more than 1000 mgs. It is clear from PART 1 of 
this study that in fact much smaller doses are required. Only 9 cases needed 
more than 65 mgs over 24 hours. 
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A study of atropine pharmaco-kinetics cannot be expected to be helpful 
in formulating a dosing protocol. This is partly because drug distribution in 
body compartments cannot predict how much drug will inhibit the cholinergic 
receptors which are being overstimulated by an unknown dose of 
acetylcholine esterase inhibitor. Earlier studies have not shown correlation of 
pseudo cholinesterase levels of mortality, or severity of illness, but are helpful 
in diagnosis. 
For the above reasons it was decided to use the data obtained in part I 
to formulate the algorithm to be used in Part II.A decremental pattern was 
chosen as the study indicated that higher doses were needed initially, and 
smaller doses were required subsequently. A total of 60 mg per day was used 
as guided by Part 1 results, followed by decreasing doses. The results 
obtained in Part II shows that the protocol was successful in the first 24 hours 
of the study, wherein majority of the patients did not need excess atropine 
than planned. However from the 24 hour onwards, more number of patients 
needed dose adjustment. A major achievement was rapid atropinisation. The 
maximum atropine required to stabilize patient initially before the infusion was 
begun was 34 mgs. This amount was administered within 15-20 minutes after 
arrival as per the protocol. The results show that some fine-tuning of the 
algorithm needs to be done, and retested to see if it is more suitable. This 
study shows that a protocol based dose regimen of atropine may be useful in 
the early management of organophosphorus poisoning. As time passes by the 
patients requirement are different and difficult to predict, probably due to the 
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different load of poison taken, different built, body fat content and the type of 
poison taken.       
It is possible that no algorithm will be effective for all patients, but one which is 
efficacious 80% of the time, will be a great advance. More study is needed to 
see if the dose of atropine varies according to the compound used and the 
dose of the poison ingested .The reasons for persisting with finding a suitable 
algorithm are very cogent. An easy to follow algorithm allows freeing up of 
skilled nursing time especially in secondary care centers where nurses and 
doctors may be in short supply, or engaged in looking after other ill patients. 
Atropine toxicity is common if high doses as recommended in literature 
are given for many hours without supervision. While high doses ensure that no 
death occurs due to bradyarrythmias, there is a high incidence of intense 
central nervous system stimulation. This is very detrimental as it causes 
dehydration, hyperpyrexia, severe restlessness, and possibly results in 
increased mortality. In both parts of the study, the atropine toxicity was found 
to be very low. 
The mortality in part 1 was 8.33 % and in the second was slightly 
though not significantly higher at 12%. The study was not designed to 
compare mortality as an outcome. It can be inferred however that use of the 
algorithm did not cause a detrimental effect of increased mortality. 
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In this study a control arm was not studied in Part II. The reason for this 
was that this was an efficacy and safety study designed to show that an 
algorithmic approach is feasible and does not increase toxicity and other 
complications. However to compare outcomes like mortality the best study 
design would be a randomised controlled trial comparing the protocol with the 
current practice. This study proves safety and efficacy in early stages. Further 
study should be done as a double blind randomized controlled trial to compare 
an algorithmic dosing schedule, to an individualized dosing pattern. 
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                                                    CONCLUSION 
 
 
The results of this study shows the following- 
 
1.        Administration of atropine using a fixed algorithm is easy and effective 
in administring the atropine requirement in the management of early 
phase of acute organophosphorus poisoning.  
2. Smaller doses of atropine are sufficient in treating cases of OP 
poisoning, than those recommended in literature. This resulted in less 
atropine toxicity, without increasing complications. 
3.  More studies are required to predict and study causes of wide variability 
in atropine requirements. 
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                                                         LIMITATIONS 
 
1.  The study is done on a small number of patients. 
 
2.  The study was not designed to compare outcomes such as mortality.  
 
3.  Many patients enrolled into the study were referred from a peripheral 
hospital and treatment received there might have had some influence 
on the requirement of atropine. 
 
4.  All patients did not receive the same standard of care as some of them 
were managed in the general wards due to non availability of beds in 
the ICU. 
 
5.  The study involved only the moderate to severe organophosphorus 
poisoned patients. Many of them requiring mechanical ventilation were 
also sedated, this may have had masked the mild features of atropine 
toxicity. 
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APPENDIX-I 
Severity grading of organophosphorus poisoning by Namba et al 36 
 
Severity score symptoms Serum BuChE levels 
(%) 
Mild Dizziness, nausea, 
vomiting, diarrhea, 
abdominal pain, 
salivation and wheezing. 
20 – 50 % 
Moderate All of the above and 
weakness, inability to 
walk, fasciculations, 
dysarthria, miosis. 
10 – 20 % 
Severe All of the above and 
coma, flaccid paralysis, 
pulmonary edema, 
respiratory distress. 
< 10 % 
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Organo phosphorus poisonoing study( Part I) data collection sheet. 
Hospital number 
Sex 
Age 
Compound 
Known psychiatric illness 
Time gap at presentation 
CLINICAL FEATURES 
Miosis 
Bronchorrhea 
Micturition 
Diarrhea 
Bradycardia 
Hypotension 
Crackles 
Intubation at admission 
ATROPINE DOSE (mg) 
Day 1 0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-24 
Atropine 
dose 
infusion 
             
Additional              
Total              
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 Day 1 Day 2 Day 3 Day 4 
Infusion     
Additional     
Total     
Atropine toxicity  Y/N ,    HR-     ,   Dose of atropine 
Pseudocholinesterase 
Intermediate syndrome 
Duration of ventilation 
Time to regain consiousness 
Complications 
Antibiotics used 
Infection   -    UTI / LRI / LINE 
Fever 
Premorbid condition- 
Outcome -- alive / dead. 
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Data abstraction form – Organophosphate poisoning study 
PATIENT SERIAL NUMBER: 
Name:      Hospital Number:    
Age:       Sex:    State: 
Name of Pesticide:    Type:  Dimethyl / Diethyl / Unknown 
Amount consumed(ml) :    Source: 
Date/Time of consumption:  
Pre-hospital treatment: 
Gastric lavage given:  Yes / No   Atropine: Yes / No  
Oximes: Yes / No    If yes dose:  Time given: 
Cardiac/Respiratory arrest: Yes / No  Ventilation: Yes / No 
At admission: (Circle features present at admission) 
Bradycardia Tachycardia Arrhythmia 
Hypotension Hypertension Ventricular Fib 
Miosis Mydriasis Tachypnea 
Paradoxical respiration Respiratory arrest Aspiration pneumonia 
Seizures Acute renal failure Leukocytosis 
Electrolyte abnormality GCS Pseudo chol 
In hospital data (circle features observed) 
Cardiac arrest Arrhythmias Hypotension 
Ventricular fibrillation Aspiration pneumonia Nosocomial pneumonia 
Nosocomial UTI Septicaemia Acute renal failure 
Hepatic dysfunction Pancreatitis Atropine toxicity 
Organisms identified & site: 
 
Days 1 2 3 4 5 6 7 
Atropine dose 
planned (mg) 
       
Additional dose        
Total dose        
 
Day1  0-2 hrs 3-4 hrs 5-6 hrs 7-8 hrs 9-24 hrs 
Atropine dose 
planned (mg) 
     
Additional dose      
Total dose      
 
Intermediate syndrome:  Yes / No  If yes onset time: 
Ventilation: Yes / No    If yes duration (days): 
Tracheostomy: Yes / No   If yes day of tracheostomy  
                                                                        (after poisoning): 
 
Duration of ICU stay (days):   Duration of hospital stay (days): 
 
ICU outcome:  Dead / Alive / Discharged at request/ PVS 
Hospital outcome:  Dead / Alive / Discharged at request / PVS 
 
 
Total cost (Rs):  
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    Appendix  6:   Key to data sheet part I    
                                                                 
VARIABLE EXPANSION CODE 1 CODE 2 VALUE 
sex 
age 
psyill 
miosis 
pulmsec 
brady 
hypotens 
crackles 
admintub 
atrhr1 
atrhr2 
atrhr3 
atrhr4 
atrhr5 
atrhr6 
atrhr7 
atrhr8 
atrhr9 
atrhr10 
atrhr11 
sex 
age 
psychiatry illness 
miosis at admission 
pulmonary secretions at 
 admission 
bradycardia at admission 
hypotension at admission 
crackles at admission 
intubated at admission 
atropine requirement hour 1 
atropine requirement hour 2 
atropine requirement hour 3 
atropine requirement hour 4 
atropine requirement hour 5 
atropine requirement hour 6 
atropine requirement hour 7 
atropine requirement hour 8 
atropine requirement hour 9 
atropine requirement hour 10 
Male 
 
Present 
Present 
Present 
Present 
Present 
Present 
Yes 
 
 
 
 
 
 
 
 
 
 
 
Female 
 
Absent 
Absent 
Absent 
Absent 
Absent 
Absent 
No 
 
 
 
 
 
 
 
 
 
 
 
 
years 
 
 
 
 
 
 
 
 mgs 
 mgs 
 mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
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atrhr12 
at13to24 
atrday2 
atrday3 
atrday4 
atrtox 
pseudoch 
intsynd 
durvent 
concious 
antibiot 
infectio 
fever 
premorbi 
outcome 
atropine requirement hour 11 
atropine requirement hour 12 
atropine requirement hour 13 to 
 24 
atropine requirement day 2 
atropine requirement day 3 
atropine requirement day 4 
atropine toxicity 
pseudocholinesterase at 
 admission 
intermediate syndrome 
duration of ventilation 
time to regain consiousness 
antibiotic used 
infections developed 
fever in hospital 
premorbid illness 
hospital outcome 
 
 
 
 
 
Develope
d 
 
Develope
d 
 
 
Yes 
Yes 
Yes 
Present 
Alive 
 
 
 
 
 
 
Not developed 
 
Not developed 
 
 
No 
No 
No 
Absent 
Dead 
 
mgs 
mgs 
mgs 
mgs 
mgs 
 
IU/L 
 
Hours 
Hours 
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    Appendix  7:   Key to data sheet part II   
                                                                  
VARIABLE EXPANSION CODE 1 CODE 2 VALUE  
name 
hospno 
age 
sex 
opclass 
amount 
glavage 
atropine 
oximes 
arrest 
ventilat 
brady 
hypotens 
miosis 
paradoxb 
seizures 
electrol 
tachycar 
hyperten 
mydriasi 
resparre 
arf 
gcs 
arrythmi 
vfib 
tachypne 
aspirati 
name 
hospital number 
age 
sex 
organophosphorus class 
amount consumed (ml) 
gastric lavage 
pre hospital atropine treatment 
pre hospital oximes treatment 
prehospital cardiac/respiratory 
arrest 
pre hospital ventilation 
bradycardia at admission 
hypotension at admission 
miosis at admission 
paradoxical respiration at 
admission 
seizures at admission 
electrolyte abnormality at 
admission 
tachycardia at admission 
hypertension at admission 
mydriasis at admission 
respiratory arrest at admission 
acute renal failure at admission 
GCS at admission 
arrythmia at admission 
 
 
 
Male 
Dimethyl 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
 
 
Female 
Diethyl 
 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Name 
Number 
Years 
 
 
ml 
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leucocyt 
pseudoch 
hcardarr 
hvfib 
huti 
hhepdys 
harryth 
haspirat 
hsepsis 
hpancrea 
hhypoten 
hpneumon 
harf 
hatrtox 
organism 
siteorg 
 
ventricular fibrillation 
tachypnea at admission 
aspiration pneumonia at admission 
leucocytosis at admission 
pseudocholinesterase at 
admission 
cardiac arrest in hospital 
ventricular fibrillation in hospital 
nosocomial UTI 
hepatic dysfunction in hospital 
arrythmias in hospital 
aspiration pneumonia in hospital 
septicaemia in hospital 
pancreatitis in hospital 
hypotension in hospital 
nosocomial pneumonia 
acute renal failure in hospital 
atropine toxicity in hospital 
organism identified 
site of infection 
 
Yes 
Yes 
 
Yes 
Yes 
Yes 
Yes 
Yes 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
 
No 
No 
 
No 
No 
No 
No 
No 
 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
 
 
 
 
3 -15 
 
 
 
 
 
IU/L 
 
 
 
 
 
 
 
 
 
 
Name 
Site 
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VARIABLE EXPANSION CODE 1 CODE 2 VALUE 
iniatrop 
hr1to2 
hr3to4 
hr5to6 
hr7to8 
hr9to24 
day1 
day2 
day3 
day4 
intsyn 
onsettim 
hventila 
ventdur 
trach 
trachday 
duricu 
durhosp 
icuoutco 
houtcome 
initial atropinisation dose of 
atropine  
atropine requirement hour 0-2 
atropine requirement hour 3-4 
atropine requirement hour 5-6 
atropine requirement hour 7-8 
atropine requirement hour 9-24 
total atropine requirement day 1 
total atropine requirement day 2 
total atropine requirement day 3 
total atropine requirement day 4 
developed intermediate syndrome 
onset time for intermediate 
syndrome  
ventilation requirement 
duration of ventilation  
tracheostomy done 
day of tracheostomy after 
poisoning 
duration of ICU stay 
duration of hospital stay 
ICU outcome 
hospital outcome 
 
 
 
 
 
 
 
 
 
 
Yes 
 
Yes 
 
Yes 
 
 
 
Alive 
Alive 
 
 
 
 
 
 
 
 
 
 
No 
 
No 
 
No 
 
 
 
Dead 
Dead 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
mgs 
 
days 
 
days 
 
days 
days 
days 
 
 
 
